{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:47:07Z","timestamp":1789948027139,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.pbb.2009.08.001","type":"journal-article","created":{"date-parts":[[2009,8,20]],"date-time":"2009-08-20T08:16:35Z","timestamp":1250756195000},"page":"148-153","source":"Crossref","is-referenced-by-count":80,"title":["Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease"],"prefix":"10.1016","volume":"94","author":[{"given":"D\u00e9nes","family":"Z\u00e1dori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Geisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enik\u0151","family":"V\u00e1mos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Kliv\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2009.08.001_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.nurt.2008.01.008","article-title":"Symptomatic treatment of Huntington disease","volume":"5","author":"Adam","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pbb.2009.08.001_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1212\/WNL.27.2.193","article-title":"Long-term treatment of juvenile Huntington\u2019s chorea with dipropylacetic acid","volume":"27","author":"Bachman","year":"1977","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2009.08.001_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jnr.1244","article-title":"NMDA receptor function in mouse models of Huntington's disease","volume":"66","author":"Cepeda","year":"2001","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pbb.2009.08.001_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","article-title":"Transcriptional dysregulation in Huntington's disease","volume":"23","author":"Cha","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pbb.2009.08.001_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/263244a0","article-title":"Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea","volume":"263","author":"Coyle","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2009.08.001_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.ejhg.5200781","article-title":"Predictive DNA-testing for Huntington's disease and reproductive decision making: a European collaborative study","volume":"10","author":"Evers-Kiebooms","year":"2002","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.pbb.2009.08.001_bib7","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington\u2019s disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.pbb.2009.08.001_bib8","first-page":"168","article-title":"Huntington disease in Maryland: clinical aspects of racial variation","volume":"41","author":"Folstein","year":"1987","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pbb.2009.08.001_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease","volume":"280","author":"G\u00e1rdi\u00e1n","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pbb.2009.08.001_bib10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00702-004-0201-4","article-title":"Huntington\u2019s disease: pathomechanism and therapeutic perspectives","volume":"111","author":"G\u00e1rdi\u00e1n","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pbb.2009.08.001_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0920-1211(88)90024-1","article-title":"Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons","volume":"2","author":"Gram","year":"1988","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.pbb.2009.08.001_bib12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM200009283431316","article-title":"Improvement of Huntington's disease with olanzapine and valproate","volume":"343","author":"Grove","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pbb.2009.08.001_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.0022-3042.2001.00728.x","article-title":"Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation","volume":"80","author":"Hashimoto","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.pbb.2009.08.001_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1602\/neurorx.1.3.298","article-title":"Translating therapies for Huntington's disease from genetic animal models to clinical trials","volume":"1","author":"Hersch","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.pbb.2009.08.001_bib15","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pbb.2009.08.001_bib16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1471-4159.1979.tb05250.x","article-title":"Differential effects of n-dipropylacetate and amino-oxyacetic acid on gamma-aminobutyric acid levels in discrete areas of rat brain","volume":"33","author":"Iadarola","year":"1979","journal-title":"J Neurochem"},{"key":"10.1016\/j.pbb.2009.08.001_bib17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001756-200303240-00007","article-title":"Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation","volume":"14","author":"Igarashi","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.pbb.2009.08.001_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.pbb.2009.08.001_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pneurobio.2007.02.005","article-title":"Drug targeting of dysregulated transcription in Huntington's disease","volume":"83","author":"Kazantsev","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pbb.2009.08.001_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/JNEUROSCI.20-01-00001.2000","article-title":"Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine","volume":"20","author":"Kliv\u00e9nyi","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.pbb.2009.08.001_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbr.2006.01.003","article-title":"Behaviour changes in a transgenic model of Huntington's disease","volume":"169","author":"Kliv\u00e9nyi","year":"2006","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2009.08.001_bib22","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1046\/j.1471-4159.2003.02263.x","article-title":"Mice deficient in dihyrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity","volume":"88","author":"Kliv\u00e9nyi","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.pbb.2009.08.001_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.14712\/fb2007053020037","article-title":"Valproic acid, a molecular lead to multiple regulatory pathways","volume":"53","author":"Kostrouchov\u00e1","year":"2007","journal-title":"Folia Biol (Praha)"},{"key":"10.1016\/j.pbb.2009.08.001_bib24","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","article-title":"The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2","volume":"22","author":"Kr\u00e4mer","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.pbb.2009.08.001_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1568007053005091","article-title":"Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents","volume":"4","author":"Langley","year":"2005","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.pbb.2009.08.001_bib26","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1471-4159.1981.tb00595.x","article-title":"Effect of inhibitors of GABA aminotransferase on the metabolism of GABA in brain tissue and synaptosomal fractions","volume":"36","author":"L\u00f6scher","year":"1981","journal-title":"J Neurochem"},{"key":"10.1016\/j.pbb.2009.08.001_bib27","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/0006-2952(81)90323-3","article-title":"Valproate induced changes in GABA metabolism at the subcellular level","volume":"30","author":"L\u00f6scher","year":"1981","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pbb.2009.08.001_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-0082(98)00075-6","article-title":"Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action","volume":"58","author":"L\u00f6scher","year":"1999","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pbb.2009.08.001_bib29","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/0006-2952(85)90645-8","article-title":"In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synaptosomal) GABA levels in discrete brain areas of the rat. Correlation to pharmacological activities","volume":"34","author":"L\u00f6scher","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pbb.2009.08.001_bib30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/263517a0","article-title":"Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids","volume":"263","author":"McGeer","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2009.08.001_bib31","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/01.WCB.0000138666.25305.A7","article-title":"Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high affinity glutamate uptake","volume":"24","author":"Morland","year":"2004","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.pbb.2009.08.001_bib32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/archneur.1977.00500170062012","article-title":"Valproate sodium in Huntington chorea","volume":"34","author":"Pearce","year":"1977","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pbb.2009.08.001_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ilar.48.4.356","article-title":"Animal models of Huntington's disease","volume":"48","author":"Ramaswamy","year":"2007","journal-title":"ILAR J"},{"key":"10.1016\/j.pbb.2009.08.001_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/156720506778249407","article-title":"Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death)","volume":"3","author":"Sadri-Vakili","year":"2006","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.pbb.2009.08.001_bib35","first-page":"6:11","article-title":"Dose-dependent improvement of myoclonic hyperkinesias due to Valproic acid in eight Huntington's Disease patients: a case series","volume":"28","author":"Saft","year":"2006","journal-title":"BMC Neurol"},{"key":"10.1016\/j.pbb.2009.08.001_bib36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jns.2007.01.033","article-title":"Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders","volume":"257","author":"Sas","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pbb.2009.08.001_bib37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.nbd.2005.08.001","article-title":"Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease","volume":"21","author":"Shehadeh","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pbb.2009.08.001_bib38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2009.08.001_bib39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/ajp.135.3.352","article-title":"Sodium valproate in Huntington's disease","volume":"135","author":"Symington","year":"1978","journal-title":"Am J Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.pbb.2009.08.001_bib40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0361-9230(80)90102-1","article-title":"Effects of GAD and GABA-T inhibitors on GABA metabolism in vivo","volume":"5","author":"Taberner","year":"1980","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pbb.2009.08.001_bib41","first-page":"72:971","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.pbb.2009.08.001_bib42","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pbb.2009.08.001_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0091-3057(91)90211-J","article-title":"Comparative behavioural and neurochemical studies with striatal kainic acid- or quinolinic acid-lesioned rats","volume":"39","author":"V\u00e9csei","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2009.08.001_bib44","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0006-3223(95)00377-0","article-title":"Huntington's disease, behavioural disturbances, and kynurenines: preclinical findings and therapeutic perspectives","volume":"39","author":"V\u00e9csei","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2009.08.001_bib45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF02815111","article-title":"Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone Balb\/c mice","volume":"27","author":"Vriend","year":"1996","journal-title":"Mol Chem Neuropathol"},{"key":"10.1016\/j.pbb.2009.08.001_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2007-971176","article-title":"Huntington\u2019s disease","volume":"27","author":"Walker","year":"2007","journal-title":"Semin Neurol"},{"key":"10.1016\/j.pbb.2009.08.001_bib47","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1126\/science.2841762","article-title":"NMDA receptor losses in putamen from patients with Huntington\u2019s disease","volume":"241","author":"Young","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.pbb.2009.08.001_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0006-8993(91)90078-A","article-title":"Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro","volume":"544","author":"Zeise","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2009.08.001_bib49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0896-6273(02)00615-3","article-title":"Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington\u2019s disease","volume":"33","author":"Zeron","year":"2002","journal-title":"Neuron"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305709002457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305709002457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T20:09:59Z","timestamp":1739304599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305709002457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0091305709002457"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2009.08.001","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}